We're Supporting COVID-19 Research
In times of crisis we all need to step up and help. Effective immediately, we are offering TrialStat’s eClinical Platform and Data Analytics Portal at discounted rates to researchers working on solutions related to COVID-19. With a focus on ease of use, speed of implementation, and real-time data analytics, TrialStat’s data capture suite enables fast study start up and ensures all stakeholders have relevant, customized, timely insight into all aspects of study data and areas of risk or potential delays. We welcome the opportunity to collaborate with our industry colleagues on the path to treatments or cures – please contact [email protected] to learn more about this program.
From the entire TrialStat team, we wish you and yours good health as our industry and our communities work together to navigate this outbreak over the coming weeks and months. Thank you for #StayingHome and #FlatteningTheCurve!
Our Latest COVID-19 Research News
Fluvoxamine May Prevent Clinical Deterioration in Mild COVID-19
Excerpt from the article: Fluvoxamine, an antidepressant used to treat obsessive-compulsive disorder, may help prevent clinical deterioration of patients with mild coronavirus disease 2019 (COVID-19), results of an early clinical trial suggest. The double-blind, placebo-controlled, randomized study, published in JAMA, included 152 outpatients with COVID-19 in the St. Louis area between April 10 and August…
Read More 
Celltrion concludes enrolment in global Covid-19 antibody trial
Excerpt from the Press Release: Celltrion Group has completed enrolment of 327 patients with mild-to-moderate SARS-CoV-2 infection symptoms to evaluate anti-Covid-19 monoclonal antibody treatment candidate CT-P59 in the global Phase II clinical trial. Celltrion Group has completed enrolment of 327 patients with mild-to-moderate SARS-CoV-2 infection symptoms to evaluate anti-Covid-19 monoclonal antibody treatment candidate CT-P59 in…
Read More 
Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–Adagio Therapeutics, Inc., today pre-published in vitro and in vivo data demonstrating its lead antibody candidate, ADG2, shows similar or higher potency against SARS-CoV-2 compared to monoclonal antibodies (mAbs) in clinical development, while also uniquely offering broad neutralization against a range of sarbecoviruses that pose a threat to…
Read More 
Fluidigm COVID-19 Community Connect Program Builds a Network of Testing Partners to Increase Access of Saliva-Based SARS-CoV-2 Testing for Communities
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced COVID-19 Community Connect, a program to link federal, state and local governmental entities, public health agencies, academic institutions, workforces, individuals and…
Read More 
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
Excerpt from the Press Release: RADNOR, Pa. and GENEVA, Nov. 13, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) (“Relief”) announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating respiratory failure in patients with Critical…
Read More 
Hope Biosciences Stem Cell Research Foundation Selects Phlexglobal to Support Rapid, Compliant Investigational New Drug Application for COVID-19 Therapy
Excerpt from the Press Release: Phlexglobal, a leading innovative technology and services provider for the life sciences industry, today announces that Hope Biosciences Stem Cell Research Foundation has selected Phlexglobal’s advanced SaaS solution, PhlexSubmission, to enhance the efficiency and quality of its eCTD submissions process. As an organization dedicated to advancing research through innovative protocols…
Read More 
Sorrento Announces FDA IND Filing Today for COVI-AMG Neutralizing and High Potency Antibody Against SARS-CoV-2
Excerpt from the Press Release: SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it is filing an investigational new drug application (IND) for intravenous (IV) COVI-AMG (STI-2020) to treat COVID-19 patients with mild symptoms and to evaluate safety and pharmacokinetics in healthy volunteers. Sorrento has previously…
Read More 
Stanford develops CRISPR ‘lab on a chip’ for detecting COVID-19
Excerpt from the Article: Researchers at Stanford University have developed a CRISPR-based “lab on a chip” to detect COVID-19, and are working with automakers at Ford to develop their prototype into a market-ready product. This could provide an automated, hand-held device designed to deliver a coronavirus test result anywhere within 30 minutes. In a study…
Read More 
Scanning the horizon for future Covid-19 treatments
Excerpt from the Article: Hopes of finding a magic bullet against Covid-19, at least within the next few months, rest on the outcomes of a small number of clinical trials. Beyond these leading antibody and vaccine approaches, few large clinical programmes of other novel mechanisms are under way. True, there is a huge amount of…
Read More 
NeuroRx and Relief Therapeutics announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020
Excerpt from the Press Release: RADNOR, Pa. and GENEVA, Nov. 5, 2020 /PRNewswire/ — NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF,OTCBB:RLFTF) (“Relief”) announced that the independent Data Monitoring Committee (DMC) met yesterday and voted unanimously that NCT 04311697 should continue as planned to its full enrollment of 165 patients. Specifically, the committee identified no safety concerns…
Read More 
COVID-19 vaccine is 90-percent effective: Pfizer and BioNTech
Excerpt from the Article: Pfizer Inc says its experimental COVID-19 vaccine is more than 90-percent effective, a major victory in the fight against a pandemic that has killed more than a million people, battered the world’s economy, and upended daily life. Pfizer and German partner BioNTech SE are the first drugmakers to release successful data…
Read More 
Emulate Signs Collaborative Agreement with the FDA to Apply Lung-Chip to Evaluate Safety of COVID-19 Vaccines and Protective Immunity Against SARS-CoV-2
Excerpt from the Press Release: BOSTON–(BUSINESS WIRE)–Emulate, Inc. announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Food and Drug Administration (FDA) to enable multiple studies across FDA offices in priority research areas, including programs to evaluate COVID-19 vaccines and understand human immune response against SARS-CoV-2, the…
Read More Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?